Results 1 to 10 of about 13,097,347 (378)

Encochleated Amphotericin B: Is the Oral Availability of Amphotericin B Finally Reached? [PDF]

Journal of Fungi, 2020
As the oldest and for many decades the only available agent for the treatment of life-threatening invasive fungal diseases, amphotericin B (AmB) is known for its broad-spectrum fungicidal activity against a wide range of yeasts and molds.
Maria Aigner, Cornelia Lass-Flörl
doaj   +4 more sources

Amphotericin B Revisited

MAMC Journal of Medical Sciences, 2021
Amphotericin B, one of the first systemic antifungal agents, has been in use since the past six decades. In light of the recent outbreak of mucormycosis (black fungus) cases during the second coronavirus disease 2019 wave in India, the relevance of ...
Sahil Kumar, Vandana Roy
doaj   +3 more sources

An Amphotericin B Derivative Equally Potent to Amphotericin B and with Increased Safety. [PDF]

PLoS ONE, 2016
Amphotericin B is the most potent antimycotic known to date. However due to its large collateral toxicity, its use, although long standing, had been limited. Many attempts have been made to produce derivatives with reduced collateral damage.
Armando Antillón, Alexander H de Vries, Marcel Espinosa-Caballero, José Marcos Falcón-González, David Flores Romero, Javier González-Damián, Fabiola Eloísa Jiménez-Montejo, Angel León-Buitimea, Manuel López-Ortiz, Ricardo Magaña, Siewert J Marrink, Rosmarbel Morales-Nava, Xavier Periole, Jorge Reyes-Esparza, Josué Rodríguez Lozada, Tania Minerva Santiago-Angelino, María Cristina Vargas González, Ignacio Regla, Mauricio Carrillo-Tripp, Mario Fernández-Zertuche, Lourdes Rodríguez-Fragoso, Iván Ortega-Blake   +21 more
doaj   +2 more sources

Evaluation and testing of polymethylmetacrylic (PMMA) bone cements with admixed Amphotericin B [PDF]

Journal of Orthopaedic Surgery and Research
Background Amphotericin is admixed to Polymethylmethacrylic (PMMA) spacers for fungal periprosthetic joint infections (PJI) during two-stage exchanges. We aimed to analyse the mechanical properties of PMMA cement with admixed Amphotericin B.
Florian A. Frank, Barbara Krampitz, Julia Steiner, Rainer Strathausen, Mario Morgenstern, Martin Clauss, Klaus-Dieter Kühn   +6 more
doaj   +2 more sources

Lipsosomal amphotericin B: a review of its properties, function, and use for treatment of cutaneous leishmaniasis

Research and Reports in Tropical Medicine, 2019
Mohammad Reza Shirzadi1,21Center for Communicable Diseases Control, Ministry of Health and Medical Education, Tehran, Iran; 2Center for Research of Endemic Parasites of Iran (CREPI), Tehran University of Medical Science, Tehran, IranAbstract: The genus ...
Shirzadi MR
doaj   +2 more sources

Real-World Effectiveness and Safety of Isavuconazole Versus Amphotericin B for Patients with Invasive Mucormycosis [PDF]

Microorganisms
Background: Invasive mucormycosis (IM) poses a substantial morbidity and mortality burden among immunocompromised patients. Objectives: We aim to compare the real-world effectiveness and safety of isavuconazole with those of amphotericin B in patients ...
Jiayuan Qin, Hongxia Bi, Guangmin Tang, Xinyao Liu, Junyan Qu, Xiaoju Lv, Yanbin Liu   +6 more
doaj   +2 more sources

Oral Lipid Nanocrystal Amphotericin B for Cryptococcal Meningitis: A Randomized Clinical Trial.

Clinical Infectious Diseases, 2023
BACKGROUND Amphotericin B is the gold standard treatment for severe mycoses. A new orally delivered, less-toxic formulation of amphotericin has been developed.
D. Boulware, Mucunguzi Atukunda, E. Kagimu, A. Musubire, A. Akampurira, L. Tugume, K. Ssebambulidde, J. Kasibante, L. Nsangi, Timothy Mugabi, J. Gakuru, Sarah Kimuda, Derrick Kasozi, Suzan Namombwe, Isaac Turyasingura, M. Rutakingirwa, Edward Mpoza, Enos Kigozi, C. Muzoora, J. Ellis, C. Skipper, Theresa Matkovits, P. Williamson, Darlisha A Williams, A. Fieberg, K. H. Hullsiek, M. Abassi, B. Dai, D. Meya   +28 more
semanticscholar   +1 more source

Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis

New England Journal of Medicine, 2022
Background Cryptococcal meningitis is a leading cause of HIV-related mortality in sub-Saharan Africa. Based on phase-II data, we performed a phase-III randomized controlled non-inferiority trial to determine the efficacy of a single high-dose liposomal ...
J. Jarvis, David S. Lawrence, D. Meya, E. Kagimu, J. Kasibante, Edward Mpoza, M. Rutakingirwa, K. Ssebambulidde, L. Tugume, Joshua Rhein, D. Boulware, H. Mwandumba, Melanie Moyo, H. Mzinganjira, C. Kanyama, M. Hosseinipour, Chimwemwe Chawinga, G. Meintjes, C. Schutz, K. Comins, Achita Singh, C. Muzoora, Samuel Jjunju, E. Nuwagira, M. Mosepele, Tshepo B Leeme, Keatlaretse Siamisang, C. Ndhlovu, A. Hlupeni, Constantine Mutata, E. van Widenfelt, Tao Chen, Duolao Wang, W. Hope, Timothée Boyer-Chammard, A. Loyse, S. Molloy, N. Youssouf, O. Lortholary, D. Lalloo, S. Jaffar, T. Harrison   +41 more
semanticscholar   +1 more source

Sixty years of Amphotericin B: An Overview of the Main Antifungal Agent Used to Treat Invasive Fungal Infections

Infectious Disease and Therapy, 2021
Introduced in the late 1950s, polyenes represent the oldest family of antifungal drugs. The discovery of amphotericin B and its therapeutic uses is considered one of the most important scientific milestones of the twentieth century .
F. Cavassin, João Luiz Baú-Carneiro, Rogério R. Vilas-Boas, F. Queiroz-Telles   +3 more
semanticscholar   +1 more source

Amphotericin B induced pancytopenia

Journal of Family Medicine and Primary Care, 2022
Amphotericin B (AMB) has been the irreplaceable drug of choice for countless fungal and protozoal infections. One of the lesser-known adverse effects of AMB is Pancytopenia - very rare with very few cases reported - most commonly observed following ...
Esha Vaish, Kamlesh K Gupta, Shahnawaz A Ansari, Kaushal K Singh   +3 more
doaj   +1 more source